BD Diabetes Spinoff EmbectaBTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week.

Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then.

The analysts mainly expect the patch pump market to dominate discussions, given recent developments in the market. That includes Insulet’s November announcement that it developed a basal-only patch pump for type 2 diabetes. It expects to submit for FDA 510(k) clearance for that technology “soon,” according to company officials.

Get the full story at our sister site, Drug Delivery Business News.